title: The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
abstract: OBJECTIVE
  To determine the effect of atorvastatin on postprandial lipaemia in overweight or obese women with the apoprotein (apo) E3/E3 genotype.
  
  
  METHODS
  Double-blind randomised, placebo-controlled 8-week single-centre study.
  
  
  METHODS
  Twenty-two healthy women, homozygous for apo E3 with a BMI ranging from 27.6 to 41.1 kg/m2 and normal or moderately elevated fasting triglycerides (53-184 mg/dl).
  
  
  METHODS
  After a 4-week isocaloric single-blind, placebo lead-in period, subjects were randomly assigned to receive either placebo (n = 7) or atorvastatin 20 mg once daily in the evening (n = 15) for 4 weeks.
  
  
  RESULTS
  Atorvastatin significantly reduces fasting total cholesterol, LDL-cholesterol and postprandial triglycerides in obese women, homozygous for apo E3 with normal or near-normal fasting triglyceride levels. No significant effect on fasting triglycerides was observed.
  
  
  CONCLUSIONS
  Atorvastatin decreases postprandial hyperlipidaemia, an independent cardiovascular risk factor, in normolipidaemic obese women. This effect of atorvastatin may, therefore, represent a cardioprotective mechanism.
authors.affiliation: Catholic University Leuven, University Hospital Gasthuisberg, Department of Endocrinology, Metabolism and Nutrition, Belgium. greet.vansant@uz.kuleuven.ac.be
authors.forename: G
authors.initials: G
authors.lastname: Vansant
authors.forename: A
authors.initials: A
authors.lastname: Mertens
authors.forename: E
authors.initials: E
authors.lastname: Muls
mesh_terms: D000328:Adult; D053318:Apolipoprotein E3; D001057:Apolipoproteins E / Q000097:blood / Q000235:genetics*; D000069059:Atorvastatin; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D004311:Double-Blind Method; D002149:Energy Intake / Q000502:physiology; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006720:Homozygote; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000235:genetics*; D016133:Polymerase Chain Reaction; D019518:Postprandial Period / Q000187:drug effects* / Q000502:physiology; D011758:Pyrroles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D053318:Apolipoprotein E3; D001057:Apolipoproteins E; D001786:Blood Glucose; D008076:Cholesterol, HDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014280:Triglycerides; D002784:Cholesterol; D000069059:Atorvastatin